Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Shionogi-ViiV

- PMLiVE

Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

EU approval will help drug achieve blockbuster status

- PMLiVE

NICE turns down Keytruda/Inlyta combo for kidney cancer

Cost-effectiveness agency says the long-term benefit is uncertain

- PMLiVE

GSK considers more divestments to help R&D push

Turns priority to future growth drivers and R&D investment

- PMLiVE

HIV vaccine based on Sanofi/GSK components fails trial

Data suggested vaccine was no more effective than placebo

- PMLiVE

Vyndaqel a bright spot as Pfizer comes under pressure

Faces a challenging period as big brands experience a slowdown

dengue fever mosquito

NIH starts first trial of an antibody for malaria prevention

Results should be available in the first quarter of next year

- PMLiVE

Keeping up the fight against HIV and using the lessons to tackle other threats

Danny Buckland interviews Gilead’s Mike Elliott

- PMLiVE

Pfizer signs $507m cancer deal with Effector Therapeutics

Collaboration is focused on research into evasive oncogenic target

- PMLiVE

Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer

Confirmatory trial strengthens claim in therapy area

- PMLiVE

GSK, Pfizer and Sanofi among drugmakers planning price hikes in US

Pricing pressures increase amid intense political scrutiny

- PMLiVE

FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Sets stage for lower-cost competition to big-selling drug

- PMLiVE

FDA rejects ViiV’s long-acting monthly HIV injection

Blow to company as it hopes to capture market share from Gilead

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links